TY - JOUR
T1 - FKBPL: a marker of good prognosis in breast cancer.
AU - Nelson, Laura
AU - McKeen, Hayley D
AU - Marshall, Andrea
AU - Mulrane, Laoighse
AU - Starczynski, Jane
AU - Storr, Sarah J
AU - Lanigan, Fiona
AU - Byrne, Christopher
AU - Arthur, Ken
AU - Hegarty, Shauna
AU - Ali, Ahlam Abdunnabi
AU - Furlong, Fiona
AU - McCarthy, Helen O
AU - Ellis, Ian O
AU - Green, Andrew R
AU - Rakha, Emad
AU - Young, Leonie
AU - Kunkler, Ian
AU - Thomas, Jeremy
AU - Jack, Wilma
AU - Cameron, David
AU - Jirström, Karin
AU - Yakkundi, Anita
AU - McClements, Lana
AU - Martin, Stewart G
AU - Gallagher, William M
AU - Dunn, Janet
AU - Bartlett, John
AU - O'Connor, Darran
AU - Robson, Tracy
N1 - The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Pathology, (Lund) (013030000)
PY - 2015
Y1 - 2015
N2 - FK506-binding protein-like (FKBPL) has established roles as an anti-tumor protein, with a therapeutic peptide based on this protein, ALM201, shortly entering phase I/II clinical trials. Here, we evaluated FKBPL's prognostic ability in primary breast cancer tissue, represented on tissue microarrays (TMA) from 3277 women recruited into five independent retrospective studies, using immunohistochemistry (IHC). In a meta-analysis, FKBPL levels were a significant predictor of BCSS; low FKBPL levels indicated poorer breast cancer specific survival (BCSS) (hazard ratio (HR) = 1.30, 95% confidence interval (CI) 1.14-1.49, p < 0.001). The prognostic impact of FKBPL remained significant after adjusting for other known prognostic factors (HR = 1.25, 95% CI 1.07-1.45, p = 0.004). For the sub-groups of 2365 estrogen receptor (ER) positive patients and 1649 tamoxifen treated patients, FKBPL was significantly associated with BCSS (HR = 1.34, 95% CI 1.13-1.58, p < 0.001, and HR = 1.25, 95% CI 1.04-1.49, p = 0.02, respectively). A univariate analysis revealed that FKBPL was also a significant predictor of relapse free interval (RFI) within the ER positive patient group, but it was only borderline significant within the smaller tamoxifen treated patient group (HR = 1.32 95% CI 1.05-1.65, p = 0.02 and HR = 1.23 95% CI 0.99-1.54, p = 0.06, respectively). The data suggests a role for FKBPL as a prognostic factor for BCSS, with the potential to be routinely evaluated within the clinic.
AB - FK506-binding protein-like (FKBPL) has established roles as an anti-tumor protein, with a therapeutic peptide based on this protein, ALM201, shortly entering phase I/II clinical trials. Here, we evaluated FKBPL's prognostic ability in primary breast cancer tissue, represented on tissue microarrays (TMA) from 3277 women recruited into five independent retrospective studies, using immunohistochemistry (IHC). In a meta-analysis, FKBPL levels were a significant predictor of BCSS; low FKBPL levels indicated poorer breast cancer specific survival (BCSS) (hazard ratio (HR) = 1.30, 95% confidence interval (CI) 1.14-1.49, p < 0.001). The prognostic impact of FKBPL remained significant after adjusting for other known prognostic factors (HR = 1.25, 95% CI 1.07-1.45, p = 0.004). For the sub-groups of 2365 estrogen receptor (ER) positive patients and 1649 tamoxifen treated patients, FKBPL was significantly associated with BCSS (HR = 1.34, 95% CI 1.13-1.58, p < 0.001, and HR = 1.25, 95% CI 1.04-1.49, p = 0.02, respectively). A univariate analysis revealed that FKBPL was also a significant predictor of relapse free interval (RFI) within the ER positive patient group, but it was only borderline significant within the smaller tamoxifen treated patient group (HR = 1.32 95% CI 1.05-1.65, p = 0.02 and HR = 1.23 95% CI 0.99-1.54, p = 0.06, respectively). The data suggests a role for FKBPL as a prognostic factor for BCSS, with the potential to be routinely evaluated within the clinic.
U2 - 10.18632/oncotarget.3528
DO - 10.18632/oncotarget.3528
M3 - Article
C2 - 25906750
SN - 1949-2553
VL - 6
SP - 12209
EP - 12223
JO - Oncotarget
JF - Oncotarget
IS - 14
ER -
